Beat the Cancer Death Sentence with Antiparasitics
| 49 People With Pancreatic Cancer Who Beat the Death Sentence Fenbendazole, mebendazole, and ivermectin are producing responses across four continents that oncology’s best chemotherapy cannot match |
The Worst Diagnosis in Oncology
Pancreatic ductal adenocarcinoma (PDAC) is what oncologists use when they want to explain hopelessness. Over 90% of cases carry activating mutations in KRAS — the master driver oncogene that no approved targeted therapy has successfully dismantled for the general PDAC population. The disease is almost always diagnosed late. Surgery is possible in fewer than 20% of patients. FOLFIRINOX — the most aggressive chemotherapy regimen in common use — extends median survival by a few months against gemcitabine alone. Five-year survival for Stage 4 disease: approximately 3%.
These are the numbers your oncologist will cite when they tell you to get your affairs in order. What they will not cite are the 49 documented cases — from New Zealand to New York, from Kentucky to Romania — in which patients given weeks to live are alive years later. In which tumors dismissed as untreatable have collapsed under protocols built on antiparasitic drugs that cost less than a daily cup of coffee.
This article is that record. Read it. Share it. And if you are facing this diagnosis, understand that the biological problem is solvable — even if the institutional problem is not.
Key Numbers:
- 49 — Documented pancreatic cancer cases using antiparasitic protocols (2022–2026)
- 93% — Maximum pancreatic tumor shrinkage recorded (Case No. 33)
- 99.9% — CA19-9 drop recorded (Case No. 9: from 44,960 to 21)
The Mechanism: Why Antiparasitics Hit PDAC Hard
The foundational argument of the book — Cancer Is a Parasite — is that cancer shares deep biological architecture with parasitic organisms. Nowhere is this convergence more therapeutically relevant than in PDAC. The vulnerabilities that parasites share with pancreatic cancer cells are precisely the vulnerabilities that benzimidazoles and ivermectin have been exploiting for decades in veterinary and human medicine.
Fenbendazole (FBZ) and Mebendazole (MBZ) — Eight Anticancer Mechanisms:
- Microtubule Disruption. FBZ binds β-tubulin with high affinity, depolymerizing the mitotic spindle. Cancer cells in rapid division cannot complete mitosis. Cell death follows.
- Warburg Effect Blockade. GLUT1 and GLUT4 glucose transporter suppression starves PDAC’s glycolytic dependency. KRAS-driven tumors are extraordinarily glycolytic — cut the glucose, cut the fuel.
- p53 Reactivation. FBZ stabilizes and upregulates p53 — the tumor suppressor that PDAC has silenced or mutated. Restored p53 function triggers apoptosis in tumor cells.
- Cancer Stem Cell Elimination. Both FBZ and IVM target cancer stem cells — the self-renewing subpopulation responsible for recurrence and chemoresistance that conventional chemotherapy misses entirely.
- Multidrug Resistance Reversal. IVM inhibits NF-κB pathway activation and efflux pump overexpression — the primary mechanisms driving PDAC’s notorious resistance to consecutive chemotherapy regimens.
- CYP24A1 Inhibition. FBZ blocks CYP24A1 — the enzyme tumors upregulate to destroy local vitamin D (Supple, 2026). Restored vitamin D activity re-enables immune surveillance that PDAC has suppressed.
- VEGF Pathway Suppression. FBZ reduces vascular endothelial growth factor signaling — cutting off tumor angiogenesis and, in several cases, contributing to resolution of malignant ascites.
- Chemosensitization. IVM reverses tumor resistance to concurrent chemotherapy. Cases consistently show: modest chemo response alone, then dramatic collapse once IVM is added. The mechanism is real and documented.
This is not one mechanism. It is eight — against a cancer that defeats single-pathway therapies by evolving around them. As explained in Cancer is a Parasite, the multimodal logic of antiparasitic treatment is precisely why the case series below shows responses that oncologists call miraculous. It is not a miracle. It is specific mechanisms operating on multiple axes simultaneously.
The Cases: A Global Signal
The Chemosensitization Proof-of-Concept
The most scientifically powerful cases are those that isolate the contribution of antiparasitics by providing a direct before-and-after comparison. Case 33 is the archetype.
—
Case No. 33 · France · December 2025
54-Year-Old Man — Stage 4 Pancreatic Cancer Metastatic to Liver
Five cycles of FOLFIRINOX produced only a 17% tumor burden reduction — classified as non-significant by RECIST criteria. The patient then added ivermectin (1 mg/kg/day) and mebendazole (1,500 mg/day) to ongoing chemotherapy.
Results over the next five identical chemo cycles:
- Pancreatic primary: 32 mm → 13 mm (93.3% volume reduction)
- Liver Seg 7/8 lesion: 58 mm → 45 mm (53.3% volume reduction)
- Liver Seg 7 lesion: 18 mm → 8 mm (91.2% volume reduction)
- Retroperitoneal lymph node: 11 mm → 7 mm (74.2% volume reduction)
Same chemo. Same patient. The only variable was the antiparasitics. Chemo alone = 17% reduction over 5 cycles. Chemo + IVM + MBZ = up to 93% reduction over 5 cycles. This potentiation effect is consistent across most solid tumor cancers as detailed in Cancer is a Parasite.
—
Case No. 40 · Canada · April 2026
56-Year-Old Man — Stage 4 Pancreatic Cancer
Started ivermectin and fenbendazole alongside chemotherapy in September 2025. Six-month results:
- Pancreatic mass: 40×32 mm → 17×23 mm (78% volume reduction)
- Liver lesions: 55% volume reduction
- CA19-9: 2,784 → 37
His oncologist remarked, “Cancer patients almost never see dramatic results like this with chemo alone. This is treatment synergy.”
—
Case No. 39 · Romania · March 2026
75-Year-Old Man — Stage 4 Pancreatic Cancer
Triple therapy — ivermectin + fenbendazole + mebendazole — alongside chemotherapy, started November 2025. Five-month results:
- CA19-9: 18,630 → 1,000 (95% drop)
- Pancreatic mass: 45×35 mm → 22×14 mm (92% volume shrinkage)
No Evidence of Disease — The NED Cases
Several patients achieved complete radiologic clearance — No Evidence of Disease — in a cancer where that outcome is not supposed to exist.
—
Case No. 41 · New Zealand · May 2026
70-Year-Old Man — Stage 4 Pancreatic Cancer · Given 2–3 Months to Live
Diagnosed with Stage 4 disease and given a two-to-three-month prognosis. Declined all conventional oncology. In May 2025, began ivermectin, fenbendazole, and hyperbaric oxygen therapy (HBOT).
Twelve months later: No Evidence of Disease. No chemotherapy. No radiation. No traditional oncology treatment of any kind.
—
Case No. 35 · Argentina / Quebec · January 2026
43-Year-Old Woman — Unresectable 5 cm Pancreatic Mass
Presented with a 5 cm pancreatic tail mass confirmed non-resectable by surgery in Canada. For 11 months: ivermectin (72 mg/day), fenbendazole (1,500 mg/day), mebendazole (1,500 mg/day in the final month).
CT scan with contrast at 11 months: “Pancreas appears normal with no anomalies.”
Her Argentine oncologist — in contrast to his Canadian colleagues — requested a copy of the protocol to apply to other patients.
—
Case No. 24 · Pennsylvania, USA · October 2025
53-Year-Old Man — Stage 4 Pancreatic Cancer
Started IVM (1.5 mg/kg/day), FBZ (1,500 mg/day), and chemotherapy in late March 2025. Six-month results:
- PET scan: no evidence of metabolically active disease
- Liver metastases: completely resolved
- CA19-9: 154 → 17
His oncology team repeatedly told him the disease “would come back,” characterized his recovery as “no longer a curative discussion,” and attempted to dissuade him from ordering the confirmatory PET/CT that proved his NED status.
—
Case No. 17 · Maryland, USA · June 2025
67-Year-Old Woman — Stage 4 After Failed FOLFIRINOX
Three months of neoadjuvant FOLFIRINOX: no improvement, suspected Stage 4 progression with new liver metastases. She started IVM (1.5 mg/kg/day), FBZ (1,000 mg/day), and CBD oil in early March 2025.
CT at 2.5 months:
- Pancreatic head mass: “no longer visualized”
- Liver nodules: absent
- CA19-9: 942 → 9
Complete radiologic clearance in a patient who had already failed FOLFIRINOX entirely.
The Standout Data Points
Case No. 9 · age 77, male 2025
Stage 4 Pancreatic Cancer Patient
Protocol: Mebendazole 1,000 mg (morning) + Fenbendazole 888 mg (afternoon). No ivermectin. No chemotherapy.
Results:
- CA19-9: 44,960 → 21 (99.9% reduction)
- Large liver lesion: 70% volume reduction
- Second liver lesion: 87% volume reduction
“I do not remember a person with results like this.” — His oncologist, after 35 years in practice. He called the results a miracle.
It was not a miracle. It was fenbendazole and mebendazole operating on a cancer that had no defense against their mechanisms.
—
Case No. 20 · Stage 4 pancreatic cancer. The Canadian MAID Case · 2025
A Canadian patient with Stage 4 pancreatic cancer recurrence — with lung metastases — was offered Medical Assistance in Dying (MAID) as the primary clinical recommendation.
He started fenbendazole (444 mg/day, escalating), then added ivermectin.
Result: “The CT scan showed that all signs of cancer were undetectable and essentially resolved.”
His primary oncologist was shocked by the turnaround. The patient avoided Canada’s first clinical offer — euthanasia — through a drug that costs less than a cup of coffee per dose.
What the Oncologists Said
The tumor responses documented above are extraordinary. But arguably more revealing is the institutional reaction — a pattern that repeats across nearly every case in this series.
Case No. 34 (Kentucky): The oncologist told the patient her tumor would not shrink. It shrank 82%.
Case No. 26 (Florida): A tumor shrank 56% in volume on ivermectin and fenbendazole alone, after the patient abandoned FOLFIRINOX. Official chart notation: “stable disease.”
Case No. 12 (California): When the Stanford oncologist saw the results — 81% CA19-9 drop and 46% reduction in PET metabolic activity — she was reportedly “not happy” that her patient was taking fenbendazole and ivermectin.
Case No. 24 (Pennsylvania): PET-confirmed NED. The oncology team told the patient the disease “would come back” and attempted to prevent him from ordering the confirmatory scan that documented his remission.
Case No. 9: CA19-9 dropped from 44,960 to 21. His oncologist’s response after 35 years in practice: he called it a miracle. The only oncologist in this series honest enough to admit he had no framework for what he was seeing.
Pattern Recognition: Across 49 cases, the institutional response to antiparasitic-driven remission follows a consistent sequence: (1) dismissal of the protocol, (2) minimization of the response (”stable disease”), (3) attribution of any improvement to concurrent chemotherapy, (4) warnings that the disease “will come back,” and (5) in extreme cases, active discouragement of confirmatory imaging. This is not a bug in the oncology system. It is a feature of a system whose financial architecture is incompatible with $1-per-dose treatments.
Fenbendazole vs. Mebendazole: Which Wins for Pancreatic Cancer?
Both are benzimidazoles. Both share the core mechanism of β-tubulin binding and GLUT transporter suppression. The Italian head-to-head comparison (Florio et al., Cancers 2019) gives fenbendazole a slight edge for pancreatic cancer specifically.
- Mebendazole is FDA-approved for human use — easier to obtain via prescription
- Fenbendazole is lower cost (~$1/dose) and available OTC for veterinary use
- Both are fully interchangeable when one is unavailable
- Case No. 9 (CA19-9: 44,960 → 21) used mebendazole + fenbendazole, no ivermectin
- Case No. 27 (Michigan, 50% tumor shrinkage) used mebendazole alone
Bottom line: Get whichever you can access. Both work. The combination is stronger than either alone. For pancreatic cancer specifically, the published comparative data favors fenbendazole — but mebendazole has produced landmark results on its own.
Protocol Overview from the Case Series
The following is a report of observed dosing ranges across 49 documented cases, presented for informational purposes only.
Fenbendazole
Range: 444 mg/day (low-dose responders) to 2,000 mg/day (aggressive Stage 4)
High-dose range for PDAC: 1,000–1,776 mg/day
Administration: with a fatty meal to maximize bioavailability; 6–7 days/week
Mebendazole
Range: 1,000–1,500 mg/day across all documented cases
FDA-approved for human use; fully substitutable for FBZ when unavailable
Ivermectin
Range: 12 mg/day (low-dose, still effective in Case 6) to 2 mg/kg/day
Most common range for Stage 4 PDAC: 1.0–1.5 mg/kg/day
Critical role: chemosensitizer, MDR reversal, cancer stem cell targeting
CBD Oil
100 mg/day — noted in multiple high-response cases (Cases 30, 31, 23, 16)
Anti-inflammatory and anti-proliferative synergy with benzimidazoles
Adjuncts (documented across the case series)
Modified citrus pectin 15 g/day · Vitamin D3, 2,000 – 10,000 IU/day · Curcumin 600 mg ×2 · Quercetin 500 mg · Berberine 600 mg 2–3× · Turkey tail mushroom · Zinc 50 mg · Serrapeptase.
The Signal Is Too Large to Dismiss
Forty-nine cases. Fourteen countries. Ages 33 to 78. Stages 2 through 4. Chemo-naive patients, multiple chemo-refractory patients, post-Whipple recurrences, patients given two months to live. The responses are not scattered noise — they cluster around a consistent biological signal: benzimidazoles and ivermectin are active against PDAC, and their activity is amplified by chemotherapy synergy.
The methodological caveats are real: these are anecdotal cases, subject to reporting bias and confounding from concurrent therapies. These are also the identical caveats used to suppress every important medical advance before randomized trial evidence catches up to clinical reality.
The question is not whether these 49 cases constitute proof in the RCT sense. They do not. The question is whether 49 globally distributed cases — producing biologically coherent, mechanistically explicable responses across diverse patient populations — constitute sufficient signal to demand clinical investigation. They do. Unambiguously.
What To Do With This Information
You have options your oncologist will likely not present. Not because they are dangerous — benzimidazoles have a 50-year mass drug administration safety record — but because they fall outside the institutional training and incentive structure of modern oncology.
Pancreatic cancer patients cannot wait for Phase III evidence. With a median Stage 4 survival of three to six months, you do not have the time that randomized trials require. The cases reviewed here are the evidence available now. Waiting for clinical trials to prove that a $1/dose drug is effective for pancreatic cancer is a fool’s errand.
Document everything. CA19-9 levels, imaging reports, protocol details, timeline. These case reports exist because patients and families documented what they did. Case No. 50 and beyond should be yours.
Invoke Right to Try. US legislation exists precisely for this situation. There are physicians around the world that operate telehealth practices offering integrative oncology consultation for patients seeking antiparasitic protocols, search under holistic, functional or integrative medicine specialties. (Maybe it is a good idea to start a database of these physicians for your quick access). There appears to be no reason against most of those suffering with pancreatic cancer to add antiparasitic therapy to their treatment protocol; either under the guidance of their doctor or as a self-treatment effort.
Read the science. Cancer is a Parasite: Kill It with the Safe, Over-the-Counter Antiparasitic Fenbendazole (Skyhorse/MAHA Books, 2026). The material in the book and the reference list there will arm you for every conversation you may, or may not choose to have with your oncologist.
